Assured Guaranty (AGO) Form 144 — 40,000-Share Insider Sale Notice
Rhea-AI Filing Summary
Assured Guaranty (AGO) Form 144 notice: The filer intends to sell 40,000 common shares, with an aggregate market value of $3,260,000, on the NYSE using Merrill Lynch as broker. The planned approximate sale date is 08/11/2025. The company’s reported shares outstanding are 47,615,221, making the planned sale roughly 0.084% of outstanding shares.
The 40,000 shares were acquired through the vesting of restricted stock units (RSUs) for Robert Bailenson across dates between 02/24/2024 and 02/25/2025 (individual vested amounts: 9,030; 12,505; 8,318; 8,519; 1,628). The filer reports no securities sold in the past three months for the account. The notice includes a standard representation that the seller is not aware of undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine insider sale notice; size is immaterial relative to outstanding shares.
The Form 144 reports a proposed sale of 40,000 common shares (aggregate value $3.26M) to be executed on the NYSE through Merrill Lynch. All 40,000 shares were acquired via RSU vesting between February 2024 and February 2025 by Robert Bailenson. Relative to 47,615,221 shares outstanding, the proposed disposition amounts to approximately 0.084%, a de minimis percentage that is unlikely on its own to affect market supply materially. The filing also indicates no reported sales in the prior three months and includes the standard attestation regarding material undisclosed information.
TL;DR: Disclosure aligns with Rule 144 requirements; vesting origin limits governance concerns.
The notice documents compliance with Rule 144 by identifying the number of shares, acquisition details, and the broker. The shares were received through restricted stock unit vesting rather than open-market purchase, which is explicitly stated in the filing. The absence of sales in the past three months and the use of a broker (Merrill Lynch) are consistent with orderly disposition. The filing contains the required representation about lack of undisclosed material adverse information, fulfilling standard issuer and insider disclosure obligations.